16 Papers
136 Citations
B. Zee is an academic researcher from The Chinese University of Hong Kong. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 7, co-authored 15 publications.
Chat about Author
Papers
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma
Winnie Yeo,Frankie Kf Mo,Jane Koh,Anthony T.C. Chan,Thomas W. Leung,Pun Hui,Landon L. Chan,Amanda M. Y. Tang,Jam J. Lee,Tony Mok,Paul B.S. Lai,Philip J. Johnson,B. Zee +12 more
TL;DR: In the studied HCC population, patient-reported baseline QoL provides additional prognostic information that supplements traditional clinical factors, and is a new prognostic marker for survival for patients with unresectable HCC.
117
Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma—correlation with excision repair cross-complementing-1 polymorphisms
Brigette B.Y. Ma,Edwin P. Hui,Sze Chuen Cesar Wong,Stewart Y. Tung,K. K. Yuen,Ann D. King,Stephen L. Chan,Sing F. Leung,M. K. Kam,Brian Kh Yu,B. Zee,Anthony T.C. Chan +11 more
TL;DR: GEMOX is active in the treatment of recurrent NPC and detection of single-nucleotide gene polymorphisms from genomic DNA in peripheral blood is feasible in NPC and further studies are warranted.
59
Impact of intensity-modulated radiotherapy (IMRT) on salivary gland function in early-stage nasopharyngeal carcinoma (NPC) patients: A prospective randomized study
M. K. Kam,Sing F. Leung,B. Zee,Peter H.K. Choi,Ricky M. C. Chau,Kin Yin Cheung,Joyce J. S. Suen,Peter M.L. Teo,Wing Hong Kwan,Anthony T.C. Chan +9 more
TL;DR: This randomized trial randomized patients to receive either IMRT or 2DRT, both 66Gy, without chemotherapy to detect a 40% reduction in incidence of severe xerostomia in NPC patients treated by 2-dimensional radiotherapy.
27
Risk factors and natural history of breast cancer in younger Chinese women
Winnie Yeo,Hang-Mei Lee,Amy B.W. Chan,Emily Ying Yang Chan,Miranda Cm Chan,Keeng-Wai Chan,Sharon Chan,Foon-Yiu Cheung,Polly Sy Cheung,Peter H.K. Choi,Josette Sy Chor,William Wl Foo,Wing Hong Kwan,Stephen C. K. Law,Lawrence Pk Li,Janice Wh Tsang,Yuk Tung,Lorna Ls Wong,Ting-Ting Wong,Chun-Chung Yau,Tsz-Kok Yau,B. Zee +21 more
TL;DR: Younger patients in Hong Kong are more likely to encounter risk factors associated with breast cancer development and have more aggressive tumours than their older counterparts.
23
Quality of life (QOL) for breast cancer patients receiving aprepitant versus placebo for prevention of chemotherapy induced nausea and vomiting
TL;DR: A Phase III randomized, double-blind placebo controlled trial was done to determine if there is a favourable QOL outcome for patients receiving aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
21